Merck & Co., which beefed up its biologics operations in Ireland last year, said it will do so again, investing more than $310 million to expand two sites with plans to add 330 jobs in the process. One of the sites does some of the work on its runaway immuno-oncology success Keytruda.
Merck, known as MSD outside of the U.S. and Canada, announced today that it would invest €280 million over the next three years at its biologics operation in Brinny, County Cork, and also at its vaccines and biologics facilities at Carlow.
The Kenilworth, New Jersey-based company said it will add about 120 or so jobs to its biologics and vaccine site in Carlow. The facility also does some of the work on Keytruda, which has won three FDA approvals this month alone.
The drugmaker also will add more than 200 jobs at its fermentation and sterile filling operation in Cork where it does work on a number of if products including for lung cancer, rheumatoid arthritis and for its hepatitis C program.
“Our existing portfolio and future pipeline ensure current and future employees can operate at the cutting edge of science and technology,” Ger Brennan, managing director of MSD human health in Ireland, said in a statement. “Today, our Irish sites are involved in the production of over 50% of MSD’s global top 20 products…”
Just last year, Merck unveiled plans to add to add 110 jobs at its plant in Carlow and another 50 positions to its operations in Cork.
By Eric Palmer
Source: Fierce Pharma
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
